References of "Dewit, O"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailFactors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn's disease patients (BELCRO)
De Greef, E; Mahachie John, Jestinah; Hoffman, I et al

in Gastroenterology (2012)

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailFactors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn’s disease patients (BELCRO)
De Greef, E; Mahachie John, Jestinah; Hoffman, I et al

in Acta Gastro-Enterologica Belgica (2012)

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailSafety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
De Greef, E.; Hoffman, I.; D'Haens, G. et al

in Acta Gastro-Enterologica Belgica (2012), 75(4), 425-31

Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in ... [more ▼]

Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD. [less ▲]

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis
De Greef, E; Hoffman, I; Smets, F et al

in Gastroenterology (2011), 140(5), 787

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis
De Greef, E; Hoffman, I; Smets, F et al

in Acta Gastro-Enterologica Belgica (2011), 74

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis
De Greef, E; Hoffman, I; Smets, F et al

in Journal of Crohn’s and Colitis [=JCC] (2011), 5(1), 156

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Presentation and diagnostic features
De Greef, E; Hoffman, I; Smets, F et al

in Gastroenterology (2011), 140(5), 786

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Presentation and diagnostic features
De Greef, E; Hoffman, I; Smets, F et al

in Acta Gastro-Enterologica Belgica (2011), 74

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Presentation and diagnostic features
De Greef, E; Hoffman, I; Smets, F et al

in Journal of Crohn’s and Colitis [=JCC] (2011), 5(1), 155

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailCombined functional neuroimaging (fMRI and MEG) for the guidance of epidural motor cortex stimulation in chronic refractory neuropathic pain: a pilot study.
Bourguignon, M.; De Tiège, X.; Baleriaux, D. et al

Conference (2009, March)

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailVideo capsule endoscopy in small-bowel malignancy: A multicenter Belgian study
Urbain, D.; De Looze, D.; Demedts, I. et al

in Endoscopy (2006), 38(4), 408-411

Background and Study Aims: Early diagnosis of small-bowel tumors is crucial for therapy. Video capsule endoscopy has improved the diagnosis of small-bowel diseases, but data concerning the role of this ... [more ▼]

Background and Study Aims: Early diagnosis of small-bowel tumors is crucial for therapy. Video capsule endoscopy has improved the diagnosis of small-bowel diseases, but data concerning the role of this technique in detecting small-bowel malignancy are scarce. The aim of this paper was to review all capsule endoscopy findings at Belgian hospitals, in order to evaluate the diagnostic yield of capsule endoscopy in the field of small-bowel malignancy. Patients and Methods: For this retrospective study, the seven Belgian academic hospitals where the device was being used were asked to review the findings obtained by means of video capsule endoscopy, and to collect information about the cases of small-bowel malignancy. Results: In total, 443 capsule endoscopies were performed up to November 2004, and 11 malignant small-bowel processes were detected (2.5%). The most frequent indications for performing capsule endoscopy in those 11 cases were intestinal bleeding of undefined origin or iron-deficiency anemia. The mean number of diagnostic procedures performed before capsule endoscopy was 3.6. The capsule endoscopy results had a diagnostic yield of 1.6% after classical work-up. In 55% of these cases, capsule endoscopy findings had an influence on therapy. Conclusions: Tumors of the small bowel remain a rare condition. Video capsule endoscopy is able to detect tumors undiagnosed by classical procedures in about 1.6% of cases and has an impact on the therapy in 55% of the tumor cases. [less ▲]

Detailed reference viewed: 51 (0 ULg)